Navigation Links
Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
Date:7/21/2008

SEATTLE, July 21 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received an R&D contract award from the ONR for approximately $1.6 million to optimize its lead drug candidate for hearing regeneration. SPI has developed a proprietary technology for regenerating auditory sensory cells within the inner ear of mammals involving p27Kip1, a cyclin dependent kinase inhibitor or CKI. CKIs shut down cell division or proliferation in many developing cells and tissues and are often expressed in adult organs to maintain cellular quiescence or terminal differentiation. In the hearing organ of mammals (cochlea), p27Kip1 prevents cellular proliferation and regeneration. For this reason, sensorineural hearing loss is irreversible and often progressive. Once auditory hair cells are lost they are never replaced. In p27 knockout mice, auditory hair cell regeneration occurs due to the unique ability of supporting cells to re-enter the cell cycle, proliferate and regenerate in to supporting cells and replacement hair cells. In p27 wild type mice, this proliferative and regenerative ability is absent. SPI has developed this novel technology into a drug that inhibits p27Kip1 in wild type cells and tissues, and is injecting that drug into the cochlea of deafened Guinea pigs. Results indicate that renewed supporting cell proliferation and hair cell regeneration occur in animals that have lost their hearing due to ototoxic or acoustic injury. In some animals, a return of auditory function has been observed. The ultimate goal of this work is to restore hearing to the severe to profoundly hearing impaired or deaf, especially those with recent traumatic injuries. This novel regenerating strategy may be applied to other non regenerating systems such as the brain or retina where p27Kip1 plays a similar role.

In 2005, the Office of Naval Research began funding this hearing regeneration project. This new funding brings the total level of funding on this specific p27 project to approximately $3 million.

Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or visit http://www.soundpharma.com.


'/>"/>
SOURCE Sound Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Heel Ultrasound Helps Detect Fracture Risk
2. Accuracy of ultrasound screening in pregnancy: Effects of examiner and device quality unclear
3. Simple ultrasound exam may predict osteoporosis risk
4. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
5. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
6. Siemens New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography
7. Mindrays DC-3 Color Ultrasound Gains U.S. FDA 510(k) Clearance
8. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
9. World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives
10. ALOKA to Unveil a New Compact ProSound Diagnostic Ultrasound System
11. Journal of Ultrasound In Medicine features bioeffects consensus report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- Lianluo Smart Limited (Nasdaq: LLIT ... markets and sells medical devices and wearable sleep ... and international markets, recently attended the 2016 Guangdong ... Forum, co-hosted by the Institute of Interventional Cardiology ... Provincial People,s Hospital and Cardiology Department of Guangdong ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: